Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award

USA - English

• USA - English

SINGAPORE, March 13 /PRNewswire-Asia/ -- Moleac Pte Ltd has been granted the Emerging Company of the Year 2010 Award by BioSpectrum, the leading integrated media platform for the Life Science Industry in the Asia Pacific. This award recognizes Moleac's innovative business model; its contribution to local community and business development; its ability to attract talents, funds and peer admiration; and its potential to emerge as a major success within the next three to five years.

Moleac took the ambitious bet to bring a first and innovative medicine to market within four years with limited resources. To achieve this, Moleac has identified in Traditional Medicines a number of natural ingredients and preparations, carefully selected for their efficacy and absence of side effects, which could address therapeutic gaps. In 2006, Moleac brought to market NeuroAiD, the first treatment for post stroke recovery. Clinical trials have shown that patients taking NeuroAiD within six months after a stroke have 2.4 more chance to achieve a fuller recovery. Currently, NeuroAiD is available in multiple countries from the Asia Pacific to the Middle East region and on the website http://www.neuroaid.com. NeuroAiD is the focus of CHIMES Society, the largest-ever clinical trial on stroke recovery in Asia, which aims to recruit 1,100 stroke patients.

Recent research results have confirmed that NeuroAiD supports the neuroplasticity process during recovery after stroke through Brain-Derived Neurotrophic Factor (BDNF) secretion. NeuroAiD has been shown to decrease cognitive deficits, prevent death of threatened neuronal tissue and improve functional outcomes by repairing and restoring neuronal circuits which have been damaged after a stroke.

This recognition comes as another prestigious award, after being named by Frost and Sullivan as the Entrepreneurial Company of the Year 2009. It is a good appreciation of Moleac's early achievements and developments and NeuroAiD's meaningful contribution to patients' heath in the pharmaceutical industry.

Mr. David Picard, CEO of Moleac, together with nine other award winners, received the BioSpectrum Asia Pacific Award 2010 at the award ceremony held on the 12 of March 2010 in Singapore from Ministry of State Lee Yi Shyan. Other recipients included Dr. Kallam Anji Reddy, Chairman, Dr Reddy's Labs, who received the BioSpectrum Life Time Achievement Award.

David Picard said: "BioSpectrum is the most authoritative and influential information healthcare industry in the Asia Pacific region. We are proud of this recognition of our work and the difference we aim at making every day for stroke survivors and their treating physicians."

Mr. Picard also added, "The past year, 2009, has been a positive one for NeuroAiD development. NeuroAid reaches more and more stroke patients, thanks to an increasing numbers of prescribing doctors. I am very pleased to see that we make a meaningful contribution in the long recovery journey after stroke. Our research and development team works tirelessly towards continuous optimization of NeuroAiD formula. The latest breakthrough pharmacological data paves the way for new indications of NeuroAiD in stroke prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatments in this under-served therapeutic area. We would like to thank everyone without whose support we would have never become the recipient of this award: our academic partners, our investors, and of course my colleagues who have made this project a success."

    Moleac's achievements in 2009 include:
    -- Launching NeuroAiD in new territories such as: Iran, Jordan, Thailand
       and Pakistan. NeuroAiD is now listed in 10 countries and we are
       currently reaching patients in over 25 countries through an internet
       platform
    -- Moleac receives the Award of Singapore Entrepreneurial Company of the
       Year by Frost and Sullivan.
    -- The establishment of a new office in Paris, which is located in
       Biopark, a newly created research and scientific complex to enhance
       scientific innovation in human health, as well as a subsidiary in
       Brussels to support Moleac's European expansion;
    -- Double volume of NeuroAiD sales compared to previous year

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide. http://www.moleac.net

About NeuroAiD

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries. http://www.neuroaid.com

About BioSpectrum

BioSpectrum is a leading media platform in the Asia Pacific that provides comprehensive coverage and useful insights in the exciting areas of pharmaceuticals, biotechnology, medical devices, research & development and policies. http://www.biospectrumasia.com

    Contact details:
    Kasia Kaminska
    Telephone: +65 6478 9432
    Email: [email protected]

SOURCE Moleac